Markers of Atrial Cardiopathay

NCT ID: NCT05623969

Last Updated: 2022-11-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-30

Study Completion Date

2025-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Marker of atrial cardiopathay as apredictor value of ischemic stroke

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

detection of the presence of atrial dysfunction or atrial cardiopathy and its degree among patients complaining of palpitation, with a one-year follow-up for any cardioembolic events (stroke /TIA).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Cardiopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Holter ,Echo , Speckle tracking echocardiography

A 24-h ambulatory Holter Echocardiography Speckle tracking echocardiography (STE)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients complaining of palpitation referred for Holter monitoring

Exclusion Criteria

* • Valvular AF, moderate to severe mitral/ tricuspid/ aortic stenosis or regurgitation.

* Recent myocardial infarction within 3 months.
* Acute pulmonary embolism.
* Newly onset AF during or shortly after cardiac surgery.
* Specific type of cardiomyopathy such as cardiac amyloidosis, obstructive hypertrophic cardiomyopathy.

Decompensation stage of organ failure
Minimum Eligible Age

17 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mariam Zarief Farhan

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohammed Aboelkassem Farghal, professor

Role: PRINCIPAL_INVESTIGATOR

Assiut University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mariam zarief farhan

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mariam zarief farhan, resident

Role: CONTACT

01009427245

Amr Ahmed Aly Youssef, professor

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

atrial cardiopathay

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

COVID-19 Echo Study
NCT05317962 COMPLETED
Biomarkers in Acute Cardiac Care
NCT02355457 RECRUITING